Genentech Partners with Repertoire Immune Medicines in $765M Deal to Develop T Cell-Targeted Therapies for Autoimmune Diseases

On April 23, in Cambridge, Massachusetts, Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell-targeting immunotherapies, announced that it has entered into a collaboration and license agreement with Genentech, a member of the Roche Group, to discover and develop innovative T cell-targeted immunotherapies for the treatment of autoimmune diseases. Repertoire will deploy its DECODE™ platform, which uniquely maps the immunological synapse, to discover novel therapeutic targets.Point. (Flagship-Hatched Star T Cell Therapy Company Cuts 45% of Workforce, Raises Over $350 Million in Cumulative Financing）

According to the terms of the agreement,Repertoire Immune Medicines to Lead Target Discovery Activities Using Its DECODE™ Platform to Explore Large Antigen Spaces; Genentech to Handle Preclinical and Clinical Development, as Well as Global Commercialization of Innovative Therapies Incorporating Target Discoveries. Repertoire Eligible for $35 Million Upfront Payment, Up to $730 Million in Additional Development, Regulatory, and Commercial Milestones, Plus Tiered Royalties.

Torben Straight Nissen, Chairman and CEO of Repertoire Immune Medicines and Executive Partner of Flagship Pioneering, said:"Repertoire's DECODE™ platform uniquely maps the entire immune synapse of patients, enabling the development of transformative T-cell targeted therapies for autoimmune diseases and cancer.""The vast potential breadth of DECODE's therapeutic target discovery far exceeds our own capabilities. In light of Genentech's commitment and experience as a global market leader in developing treatments for autoimmune diseases, we are thrilled to collaborate with them to provide patients with drugs that can reset the immune system and potentially offer significant therapeutic benefits."

Boris L. Zaïtra, Head of Corporate Business Development at Roche, stated:"Roche and Genentech have been investing in groundbreaking therapies for autoimmune diseases for more than 20 years, and we are proud of the therapeutic advances we have pioneered. As we seek new opportunities to make a greater impact on patients, we look forward to translating the new discoveries from DECODE™."The team at Repertoire will develop new drugs for patients with autoimmune diseases.

Follow the official account below to see the world!